1. Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
- Author
-
Yoshikazu Mutoh, Takumi Umemura, Takeshi Nishikawa, Kaho Kondo, Yuta Nishina, Kazuaki Soejima, Yoichiro Noguchi, Tomohiro Bando, Sho Ota, Tatsuki Shimahara, Shuko Hirota, Satoshi Hagimoto, Reoto Takei, Jun Fukihara, Hajime Sasano, Yasuhiko Yamano, Toshiki Yokoyama, Kensuke Kataoka, Toshiaki Matsuda, Tomoki Kimura, Toshihiko Ichihara, and Yasuhiro Kondoh
- Subjects
COVID-19 ,molnupiravir ,nirmatrelvir/ritonavir ,hospitalization ,adverse event ,older adults ,Microbiology ,QR1-502 - Abstract
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observational study assessed and compared the outcomes of COVID-19 treated with MOV and NMV/r in a real-world community setting. We included patients with confirmed COVID-19 combined with one or more risk factors for disease progression from June to October 2022. Of 283 patients, 79.9% received MOV and 20.1% NMV/r. The mean patient age was 71.7 years, 56.5% were men, and 71.7% had received ≥3 doses of vaccine. COVID-19-related hospitalization (2.8% and 3.5%, respectively; p = 0.978) or death (0.4% and 3.5%, respectively; p = 0.104) did not differ significantly between the MOV and NMV/r groups. The incidence of adverse events was 2.7% and 5.3%, and the incidence of treatment discontinuation was 2.7% and 5.3% in the MOV and NMV/r groups, respectively. The real-world effectiveness of MOV and NMV/r was similar among older adults and those at high risk of disease progression. The incidence of hospitalization or death was low.
- Published
- 2023
- Full Text
- View/download PDF